SGLT2 Inhibitors in Diabetes:

SGLT2 inhibitors (Sodium-Glucose Cotransporter-2 inhibitors) are a class of medications that have revolutionized the treatment of Type 2 Diabetes. These drugs work by blocking the SGLT2 protein in the kidneys, preventing glucose reabsorption and promoting its excretion through urine. This helps lower blood sugar levels independently of insulin. In addition to improving glycemic control, SGLT2 inhibitors have been shown to provide cardiovascular and renal benefits, reducing the risk of heart failure, kidney disease, and diabetic complications. Recent studies have also highlighted their potential role in weight loss and blood pressure reduction. Given these multiple benefits, SGLT2 inhibitors are increasingly recommended for patients with Type 2 Diabetes, especially those with coexisting cardiovascular or kidney conditions.

    Related Conference of SGLT2 Inhibitors in Diabetes:

    October 20-21, 2026

    32nd World Diabetes & Heart Congress

    Amsterdam, Netherlands
    October 22-23, 2026

    4th World congress and Expo on Diabetes

    Toronto, Canada
    February 18-19, 2027

    7th International conference on Healthcare Summit

    Singapore City, Singapore
    February 25-26, 2027

    20th International Summit on Diabetes

    London, UK
    March 23-24, 2027

    7th Annual Summit on Diabetes and Endocrinology

    Paris, France
    March 29-30, 2027

    8th Global summit on Diabetes and Endocrinology

    Amsterdam, Netherlands
    June 29-30, 2027

    23rd World Congress on Endocrinology & Diabetes

    Paris, France
    July 08-09, 2027

    35th European Diabetes Congress

    Toronto, Canada
    July 15-16, 2027

    7th International conference on Diabetic complications

    Barcelona, Spain

    SGLT2 Inhibitors in Diabetes: Conference Speakers

      Recommended Sessions

      Related Journals

      Are you interested in